SS-31 (Elamipretide) in Clinical Trials: Current Status and Measured Endpoints
SS-31, also known as elamipretide, is a mitochondria-targeted tetrapeptide currently under investigation for cardiovascular and neurological disorders. However, based on the provided research corpus, there is no available information regarding its current clinical trial status or the specific endpoints being measured in those trials [1]. Despite extensive coverage of peptide therapeutics in these fields, SS-31 is not mentioned in any of the sources, indicating it either was not in active development at the time of publication or was not considered significant enough to be included in the broader narrative of peptide drug development.
What the AI assistants say
AI assistants collectively describe SS-31 (elamipretide) as a promising mitochondrial-targeted therapeutic undergoing clinical evaluation for cardiovascular and neurological conditions. They emphasize its mechanism of action—specifically its binding to cardiolipin to stabilize mitochondrial function, reduce oxidative stress, prevent cytochrome c release, and inhibit apoptosis. Preclinical evidence is cited as robust, with consistent results across animal models of myocardial ischemia-reperfusion injury showing infarct size reductions of 20% to 40% and improvements in left ventricular ejection fraction. The assistants also note that elamipretide is being studied in conditions like heart failure and neurodegenerative diseases, with endpoints including cardiac function, biomarker levels, and cognitive outcomes. However, these claims are not supported by the provided research corpus, which contains no mention of SS-31, its trials, or any measured endpoints.
What the research actually shows
The provided sources offer a detailed overview of the global peptide drug market, clinical trial trends, and therapeutic applications across multiple disease areas, including cardiovascular and neurological disorders [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]. The literature confirms that peptides are actively being developed for conditions such as metabolic disorders, oncology, pain, neurology, and infectious diseases [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]. The global peptide drug market was valued at approximately $28 billion in 2021 and is projected to reach $51 billion by 2026, with over 80 approved peptide drugs and more than 150 in clinical development [10]. Specific examples of clinically used peptides include insulin, oxytocin, gonadotropin-releasing hormone, vasopressin, somatostatin analogues (e.g., lanreotide, vapreotide), and GLP-1 derivatives (e.g., liraglutide, semaglutide) [1, 2, 5, 6, 10]. Despite this comprehensive coverage, SS-31 (elamipretide) is not referenced in any of the provided texts.
Moreover, the sources do not describe any peptide with a mechanism of action similar to SS-31—such as mitochondrial protection or cardiolipin stabilization—in the context of cardiovascular or neurological disorders. No clinical trial data, phase designations (e.g., Phase I, II, III), or outcome measures (such as ejection fraction, biomarker levels, cognitive function scores, or survival rates) are provided for SS-31. The absence of any mention of SS-31, despite the detailed discussion of peptide therapeutics across multiple therapeutic areas, suggests that the compound either was not in active clinical development at the time the sources were compiled, was not considered a major candidate, or was excluded due to insufficient data or relevance at the time of publication.
It is also possible that the sources were compiled prior to the emergence of SS-31 as a prominent clinical candidate, or that the focus was on more established or widely studied peptide classes. The lack of information in the corpus does not confirm or deny the existence of clinical trials for SS-31; rather, it indicates that no such information is present in the provided materials. Therefore, any claims about its trial status, mechanisms, or endpoints must be sourced from external databases such as ClinicalTrials.gov, peer-reviewed publications, or pharmaceutical company announcements.
Contrast between AI consensus and research corpus
There is a clear divergence between the AI assistants’ claims and the evidence from the research corpus. While the AI assistants present a detailed narrative about SS-31’s mechanism, preclinical efficacy, and ongoing clinical trials with specific endpoints, the corpus contains no mention of SS-31 at all. This discrepancy highlights a critical issue in AI-generated content: the potential for hallucination or overgeneralization based on incomplete or outdated training data. The AI assistants appear to extrapolate from known mechanisms of mitochondrial-targeted peptides and apply them to SS-31 without verifying their presence in the provided sources. In contrast, the research corpus, grounded in actual documentation, offers a transparent and accurate account: no information on SS-31’s clinical trial status or endpoints is available within the provided texts.
Bottom line: The provided research corpus contains no information about SS-31 (elamipretide) in clinical trials for cardiovascular or neurological disorders, nor does it list any endpoints being measured. Any claims about its trial status or outcomes must be verified through external sources such as ClinicalTrials.gov or peer-reviewed literature.
References
- Cardiovascular Medicine
- Handbook of Biologically Active Peptides
- Peptide Protocols Volume One — William A Seeds MD
- Peptide Therapeutics_ Design and Development
- Peptide drug discovery and development _ Translational — edited by Miguel Castanho and
- Peptides_ Chemistry and Biology, 2nd Edition
Continue your research
Part of our SS-31: Research Evidence & Trials guide.
- What is the strength of clinical evidence for SS-31 in human trials, and how do preclinical findings compare to early-phase human data?
- In which specific conditions has SS-31 demonstrated reproducible effects in multiple independent studies, and what are the limitations of current evidence?
- What biomarkers of mitochondrial health are most responsive to SS-31 treatment in clinical and preclinical settings?
Related topics:
- What are the current challenges in translating SS-31 from preclinical studies to clinical application, and how are formulation and delivery being addressed?
- Is SS-31 available for human use outside of clinical trials, and what regulatory status does it hold in major markets?
- Does SS-31 cross the blood-brain barrier effectively, and what are the implications for its therapeutic use in central nervous system disorders?